Loading…
MARKETS
TOOLS
LEARN
Equiscale · Syntellia LLC
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $46M | $-79M | $-49M | $110M | -12.8% | 4174.5% | -31.9% |
| 2024 | $1M | $-79M | $-72M | $-70M | -17.1% | 611.9% | -1817.7% |
| 2023 | $0M | $-45M | $4M | $-42M | -10.9% | - | -115.1% |
| 2022 | $0M | $-27M | $-28M | $-25M | 62.6% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0.15 | 1.08 | 45.95 |
| Operating Revenue | 0 | 0.15 | 1.08 | 45.95 |
| Operating Expense | 27.97 | 45.70 | 81.90 | 126.75 |
| Research And Development | 22.04 | 35.98 | 65.34 | 97.58 |
| Selling General And Administration | 5.92 | 9.72 | 16.56 | 29.16 |
| Total Expenses | 27.97 | 45.70 | 81.90 | 126.75 |
| Operating Income | -27.97 | -45.55 | -80.82 | -80.80 |
| Total Operating Income As Reported | -27.97 | 2.08 | -80.82 | -68.30 |
| EBITDA | -27.39 | -44.70 | -79.42 | -79.19 |
| Normalized EBITDA | -27.39 | -92.33 | -79.42 | -91.69 |
| EBIT | -27.97 | -45.55 | -80.82 | -80.80 |
| Interest Income | 0.29 | 2.79 | 8.62 | 19.53 |
| Net Interest Income | 0.29 | 2.79 | 8.62 | 19.53 |
| Other Non Operating Income Expenses | - | 0.01 | -0.09 | -0.10 |
| Other Income Expense | - | 47.64 | -0.09 | 12.40 |
| Interest Income Non Operating | 0.29 | 2.79 | 8.62 | 19.53 |
| Net Non Operating Interest Income Expense | 0.29 | 2.79 | 8.62 | 19.53 |
| Pretax Income | -27.68 | 4.87 | -72.30 | -48.87 |
| Tax Provision | 0 | 0.69 | -0.50 | 0.01 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | 0 | 6.76 | 0 | 0 |
| Net Income Continuous Operations | -27.68 | 4.18 | -71.80 | -48.88 |
| Net Income From Continuing And Discontinued Operation | -27.68 | 4.18 | -71.80 | -48.88 |
| Net Income From Continuing Operation Net Minority Interest | -27.68 | 4.18 | -71.80 | -48.88 |
| Net Income | -27.68 | 4.18 | -71.80 | -48.88 |
| Net Income Common Stockholders | -27.68 | 0.57 | -71.80 | -48.88 |
| Net Income Including Noncontrolling Interests | -27.68 | 4.18 | -71.80 | -48.88 |
| Normalized Income | -27.68 | -36.68 | -71.80 | -61.38 |
| Diluted NI Availto Com Stockholders | -27.68 | 0.63 | -71.80 | -48.88 |
| Basic Average Shares | 19.50 | 19.50 | 9.89 | - |
| Diluted Average Shares | 19.50 | 19.50 | 9.89 | - |
| Reconciled Depreciation | 0.58 | 0.85 | 1.40 | 1.60 |
| Total Unusual Items | 0 | 47.62 | 0 | 12.50 |
| Total Unusual Items Excluding Goodwill | 0 | 47.62 | 0 | 12.50 |
| Special Income Charges | 0 | 47.62 | 0 | 12.50 |
| General And Administrative Expense | 5.92 | 9.72 | 16.56 | 29.16 |
| Other Gand A | 5.92 | 9.72 | 16.56 | 29.16 |
| Gain On Sale Of Ppe | 0 | 47.62 | 0 | 12.50 |
| Otherunder Preferred Stock Dividend | 0 | 3.61 | 0 | - |
| Average Dilution Earnings | - | 0.06 | - | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Septerna, Inc.this co. | SEPN | $1.4B | -28.93 | 3.70 | -12.8% | -16.63 |
| Monte Rosa Therapeutics, Inc. | GLUE | $1.5B | -37.97 | 6.29 | -16.6% | -30.01 |
| Aveanna Healthcare Holdings Inc. | AVAH | $1.4B | 6.42 | 7.40 | 115.3% | 10.26 |
| Maze Therapeutics, Inc. | MAZE | $1.4B | -10.72 | 3.96 | -36.9% | -8.82 |
| Healthcare Services Group, Inc. | HCSG | $1.4B |
| 23.77 |
| 2.75 |
| 11.6% |
| 14.94 |
| AtriCure, Inc. | ATRC | $1.4B | -120.63 | 2.81 | -2.3% | 79.22 |
| Precigen, Inc. | PGEN | $1.4B | -5.49 | 65.81 | -1198.6% | -5.93 |
| Integra LifeSciences Holdings Corporation | IART | $1.4B | -2.65 | 1.31 | -49.5% | -9.72 |
| MapLight Therapeutics, Inc. | MPLT | $1.4B | - | 2.98 | -35.2% | - |
| Peer Median | - | -5.49 | 3.47 | -25.9% | -5.93 | |
Historically, Sep has averaged the highest return (+55.5%); Jan the lowest (-21.2%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -16.3%Negative MonthJan 2026: -16.28% | +24.3%Positive MonthFeb 2026: +24.34% | -17.2%Negative MonthMar 2026: -17.20% | -1.1%Neutral MonthApr 2026: -1.12% | +27.1%Positive MonthMay 2026: +27.10% | +10.9%Positive MonthJun 2026: +10.89% | +2.9%Positive MonthJul 2026: +2.87% | +27.5%*Positive MonthAug 2026: +27.52% | — | — | — | — |
| 2025 | -26.2%Negative MonthJan 2025: -26.16% | -61.7%Negative MonthFeb 2025: -61.74% | -10.5%Negative MonthMar 2025: -10.51% | +20.2%Positive MonthApr 2025: +20.21% | +32.9%Positive MonthMay 2025: +32.90% | +14.3%Positive MonthJun 2025: +14.27% | +17.4%Positive MonthJul 2025: +17.41% | -2.5%Negative MonthAug 2025: -2.50% | +55.5%Positive MonthSep 2025: +55.45% | +9.5%Positive MonthOct 2025: +9.52% | +40.9%Positive MonthNov 2025: +40.87% | -3.9%Negative MonthDec 2025: -3.93% |
| 2024 | — | — | — | — | — | — | — | — | — | — | +10.5%Positive MonthNov 2024: +10.53% | -9.5%Negative MonthDec 2024: -9.45% |
| Avg±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation — the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position — all Januaries together, all Februaries together, and so on — to show whether a given month has leaned positive or negative historically. ‘Simple’ counts each month as +1 or −1. ‘Weighted’ gives larger moves more influence: +2 above +10%, −2 below −10%. With only 3 years of history for this asset, each month’s score reflects a small number of observations — read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen — at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in “Average from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
